 |
인쇄하기
취소
|
GSK symposium on Restless Legs Syndrome for Requip.
GSK Korea took a scientific symposium on Requip (ropinirole hydrochloride), the first FDA approved new drug for the treatment of the restless legs syndrome (RLS), by inviting Korean neuro and psychiatric physicians on March 16 and 17.
The symposium provided many useful informations about RLS, its characteristics, diagnosis and treatment to the attendees and also presented a report covering a...
The symposium provided many useful informations about RLS, its characteristics, diagnosis and treatment to the attendees and also presented a report covering a...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.